Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1471-2466

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience ; volume:16 ; number:1 ; day:25 ; month:8 ; year:2016 ; pages:1-9 ; date:12.2016
BMC pulmonary medicine ; 16, Heft 1 (25.8.2016), 1-9, 12.2016

Contributor: Caminati, M.
Senna, G.
Stefanizzi, G.
Bellamoli, R.
Longhi, S.
Chieco-Bianchi, F.
Guarnieri, G.
Tognella, S.
Olivieri, M.
Micheletto, C.
Festi, G.
Bertocco, E.
Mazza, M.
Rossi, A.
Vianello, A.
SpringerLink (Online service)

DOI: 10.1186/s12890-016-0290-5

URN: urn:nbn:de:1111-201609232719

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:56 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Caminati, M.
Senna, G.
Stefanizzi, G.
Bellamoli, R.
Longhi, S.
Chieco-Bianchi, F.
Guarnieri, G.
Tognella, S.
Olivieri, M.
Micheletto, C.
Festi, G.
Bertocco, E.
Mazza, M.
Rossi, A.
Vianello, A.
SpringerLink (Online service)

Other Objects (12)

"Real-life" Efficacy and Safety Aspects of 4-Year Omalizumab Treatment for Asthma

Drop-out in dual VET: why we should consider the drop-out direction when analysing drop-out

Drop-out in dual VET: Why we should consider the drop-out direction when analysing drop-out

Severe asthma and the omalizumab option

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry

Drop-out in der Weiterbildung – eine Verschränkung von Perspektiven zur (Re‑)Konstruktion des Phänomens Drop-out

Arbeitspapier

Education subsidies and school drop-out rates

Longitudinal drop-out and weighting against its bias

Omalizumab in patients with severe asthma and persistent sputum eosinophilia

Omalizumab-Therapie bei Jugendlichen mit schwerem allergischen Asthma – eine Anwendungsbeobachtung

Omalizumab-Therapie bei Jugendlichen mit schwerem allergischem Asthma – eine Anwendungsbeobachtung

The Long-Term Effectiveness and Safety of Omalizumab on Patient- and Physician-Reported Asthma Control: A Three-Year, Real-Life Observational Study

"Real-life" Efficacy and Safety Aspects of 4-Year Omalizumab Treatment for Asthma

Drop-out in dual VET: why we should consider the drop-out direction when analysing drop-out

Drop-out in dual VET: Why we should consider the drop-out direction when analysing drop-out

Severe asthma and the omalizumab option

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry

Drop-out in der Weiterbildung – eine Verschränkung von Perspektiven zur (Re‑)Konstruktion des Phänomens Drop-out

Arbeitspapier

Education subsidies and school drop-out rates

Longitudinal drop-out and weighting against its bias

Omalizumab in patients with severe asthma and persistent sputum eosinophilia

Omalizumab-Therapie bei Jugendlichen mit schwerem allergischen Asthma – eine Anwendungsbeobachtung

Omalizumab-Therapie bei Jugendlichen mit schwerem allergischem Asthma – eine Anwendungsbeobachtung

The Long-Term Effectiveness and Safety of Omalizumab on Patient- and Physician-Reported Asthma Control: A Three-Year, Real-Life Observational Study

"Real-life" Efficacy and Safety Aspects of 4-Year Omalizumab Treatment for Asthma

Drop-out in dual VET: why we should consider the drop-out direction when analysing drop-out

Drop-out in dual VET: Why we should consider the drop-out direction when analysing drop-out

Severe asthma and the omalizumab option

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry

Drop-out in der Weiterbildung – eine Verschränkung von Perspektiven zur (Re‑)Konstruktion des Phänomens Drop-out

Arbeitspapier

Education subsidies and school drop-out rates

Longitudinal drop-out and weighting against its bias

Omalizumab in patients with severe asthma and persistent sputum eosinophilia

Omalizumab-Therapie bei Jugendlichen mit schwerem allergischen Asthma – eine Anwendungsbeobachtung

Omalizumab-Therapie bei Jugendlichen mit schwerem allergischem Asthma – eine Anwendungsbeobachtung

The Long-Term Effectiveness and Safety of Omalizumab on Patient- and Physician-Reported Asthma Control: A Three-Year, Real-Life Observational Study

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

"Real-life" Efficacy and Safety Aspects of 4-Year Omalizumab Treatment for Asthma

Drop-out in dual VET: why we should consider the drop-out direction when analysing drop-out

Drop-out in dual VET: Why we should consider the drop-out direction when analysing drop-out

Severe asthma and the omalizumab option

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry

Drop-out in der Weiterbildung – eine Verschränkung von Perspektiven zur (Re‑)Konstruktion des Phänomens Drop-out

Education subsidies and school drop-out rates

Longitudinal drop-out and weighting against its bias

Omalizumab in patients with severe asthma and persistent sputum eosinophilia

Omalizumab-Therapie bei Jugendlichen mit schwerem allergischen Asthma – eine Anwendungsbeobachtung

Omalizumab-Therapie bei Jugendlichen mit schwerem allergischem Asthma – eine Anwendungsbeobachtung

The Long-Term Effectiveness and Safety of Omalizumab on Patient- and Physician-Reported Asthma Control: A Three-Year, Real-Life Observational Study

"Real-life" Efficacy and Safety Aspects of 4-Year Omalizumab Treatment for Asthma

Drop-out in dual VET: why we should consider the drop-out direction when analysing drop-out

Drop-out in dual VET: Why we should consider the drop-out direction when analysing drop-out

Severe asthma and the omalizumab option

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry

Drop-out in der Weiterbildung – eine Verschränkung von Perspektiven zur (Re‑)Konstruktion des Phänomens Drop-out

Education subsidies and school drop-out rates

Longitudinal drop-out and weighting against its bias

Omalizumab in patients with severe asthma and persistent sputum eosinophilia

Omalizumab-Therapie bei Jugendlichen mit schwerem allergischen Asthma – eine Anwendungsbeobachtung

Omalizumab-Therapie bei Jugendlichen mit schwerem allergischem Asthma – eine Anwendungsbeobachtung

The Long-Term Effectiveness and Safety of Omalizumab on Patient- and Physician-Reported Asthma Control: A Three-Year, Real-Life Observational Study

"Real-life" Efficacy and Safety Aspects of 4-Year Omalizumab Treatment for Asthma

Drop-out in dual VET: why we should consider the drop-out direction when analysing drop-out

Drop-out in dual VET: Why we should consider the drop-out direction when analysing drop-out

Severe asthma and the omalizumab option

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry

Drop-out in der Weiterbildung – eine Verschränkung von Perspektiven zur (Re‑)Konstruktion des Phänomens Drop-out

Education subsidies and school drop-out rates

Longitudinal drop-out and weighting against its bias

Omalizumab in patients with severe asthma and persistent sputum eosinophilia

Omalizumab-Therapie bei Jugendlichen mit schwerem allergischen Asthma – eine Anwendungsbeobachtung

Omalizumab-Therapie bei Jugendlichen mit schwerem allergischem Asthma – eine Anwendungsbeobachtung

The Long-Term Effectiveness and Safety of Omalizumab on Patient- and Physician-Reported Asthma Control: A Three-Year, Real-Life Observational Study

Related objects

Reset password